{"id":942,"date":"2016-07-05T06:22:29","date_gmt":"2016-07-05T11:22:29","guid":{"rendered":"http:\/\/www.masstortlawyerblog.com\/?p=942"},"modified":"2018-04-12T12:39:35","modified_gmt":"2018-04-12T17:39:35","slug":"moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use","status":"publish","type":"post","link":"https:\/\/www.molllawgroup.com\/blog\/moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use\/","title":{"rendered":"Moll Law Group Files First Lawsuit Against AstraZeneca For Injuries Sustained from Nexium Use"},"content":{"rendered":"

Moll Law Group has filed its first lawsuit<\/a> against the maker of Nexium, AstraZeneca, on behalf of a Tennessee resident who suffered severe and life-threatening injuries after being prescribed and taking the drug Nexium. Filed in the Western District of Tennessee, the complaint alleges that the defendants knew or should have known that Nexium poses a serious risk<\/a> of kidney injuries and that the drug maker failed to provide adequate instructions regarding the potentially life-threatening consequences that could result from the use of the drug.<\/p>\n

The plaintiff started taking Nexium in 2003 and continued using it until 2008, when he was diagnosed with a severe and drug-induced case of Acute Interstitial Nephritis following a biopsy. As a result of his condition, he was required to undergo dialysis three times a week and is awaiting a kidney transplant.<\/p>\n

Nexium is a type of proton pump inhibitor (PPI)\u00a0that\u00a0is used to decrease the amount of acid that the stomach produces. This type of drug is commonly used to treat gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD). Originally approved under the name Losec in 1988, Nexium is a second-generation PPI drug and was intended to be an improvement on the first-generation version, commonly referred to as Prilosec.<\/p>\n

Continue reading \u2192<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Moll Law Group has filed its first lawsuit against the maker of Nexium, AstraZeneca, on behalf of a Tennessee resident who suffered severe and life-threatening injuries after being prescribed and taking the drug Nexium. Filed in the Western District of Tennessee, the complaint alleges that the defendants knew or should have known that Nexium poses […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-942","post","type-post","status-publish","format-standard","hentry","category-pharmaceuticals"],"yoast_head":"\nMoll Law Group Files First Lawsuit Against AstraZeneca For Injuries Sustained from Nexium Use — Illinois Injury and Mass Tort Lawyer Blog — July 5, 2016<\/title>\n<meta name=\"description\" content=\"Moll Law Group has filed its first lawsuit against the maker of Nexium, AstraZeneca, on behalf of a Tennessee resident who suffered severe and — July 5, 2016\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.molllawgroup.com\/blog\/moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Moll Law Group Files First Lawsuit Against AstraZeneca For Injuries Sustained from Nexium Use — Illinois Injury and Mass Tort Lawyer Blog — July 5, 2016\" \/>\n<meta name=\"twitter:description\" content=\"Moll Law Group has filed its first lawsuit against the maker of Nexium, AstraZeneca, on behalf of a Tennessee resident who suffered severe and — July 5, 2016\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Moll Law Group\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moll Law Group Files First Lawsuit Against AstraZeneca For Injuries Sustained from Nexium Use — Illinois Injury and Mass Tort Lawyer Blog — July 5, 2016","description":"Moll Law Group has filed its first lawsuit against the maker of Nexium, AstraZeneca, on behalf of a Tennessee resident who suffered severe and — July 5, 2016","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.molllawgroup.com\/blog\/moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use\/","twitter_card":"summary_large_image","twitter_title":"Moll Law Group Files First Lawsuit Against AstraZeneca For Injuries Sustained from Nexium Use — Illinois Injury and Mass Tort Lawyer Blog — July 5, 2016","twitter_description":"Moll Law Group has filed its first lawsuit against the maker of Nexium, AstraZeneca, on behalf of a Tennessee resident who suffered severe and — July 5, 2016","twitter_misc":{"Written by":"Moll Law Group","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.molllawgroup.com\/blog\/moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use\/#article","isPartOf":{"@id":"https:\/\/www.molllawgroup.com\/blog\/moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use\/"},"author":{"name":"Moll Law Group","@id":"https:\/\/www.molllawgroup.com\/blog\/#\/schema\/person\/53d2eb37d5d0cdb46ac61abacf05ce90"},"headline":"Moll Law Group Files First Lawsuit Against AstraZeneca For Injuries Sustained from Nexium Use","datePublished":"2016-07-05T11:22:29+00:00","dateModified":"2018-04-12T17:39:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.molllawgroup.com\/blog\/moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use\/"},"wordCount":582,"articleSection":["Pharmaceuticals"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.molllawgroup.com\/blog\/moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use\/","url":"https:\/\/www.molllawgroup.com\/blog\/moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use\/","name":"Moll Law Group Files First Lawsuit Against AstraZeneca For Injuries Sustained from Nexium Use — Illinois Injury and Mass Tort Lawyer Blog — July 5, 2016","isPartOf":{"@id":"https:\/\/www.molllawgroup.com\/blog\/#website"},"datePublished":"2016-07-05T11:22:29+00:00","dateModified":"2018-04-12T17:39:35+00:00","author":{"@id":"https:\/\/www.molllawgroup.com\/blog\/#\/schema\/person\/53d2eb37d5d0cdb46ac61abacf05ce90"},"description":"Moll Law Group has filed its first lawsuit against the maker of Nexium, AstraZeneca, on behalf of a Tennessee resident who suffered severe and — July 5, 2016","breadcrumb":{"@id":"https:\/\/www.molllawgroup.com\/blog\/moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.molllawgroup.com\/blog\/moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.molllawgroup.com\/blog\/moll-law-group-files-first-lawsuit-astrazeneca-injuries-sustained-nexium-use\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.molllawgroup.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Moll Law Group Files First Lawsuit Against AstraZeneca For Injuries Sustained from Nexium Use"}]},{"@type":"WebSite","@id":"https:\/\/www.molllawgroup.com\/blog\/#website","url":"https:\/\/www.molllawgroup.com\/blog\/","name":"Illinois Injury and Mass Tort Lawyer Blog","description":"Published by Illinois Injury and Mass Tort Attorney \u2014 Moll Law Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.molllawgroup.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.molllawgroup.com\/blog\/#\/schema\/person\/53d2eb37d5d0cdb46ac61abacf05ce90","name":"Moll Law Group","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/0febdc96ea554e620e775358f9d7e4fc56616188dfd2bb21b18c2fed4bd185a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0febdc96ea554e620e775358f9d7e4fc56616188dfd2bb21b18c2fed4bd185a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0febdc96ea554e620e775358f9d7e4fc56616188dfd2bb21b18c2fed4bd185a0?s=96&d=mm&r=g","caption":"Moll Law Group"}}]}},"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts\/942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/comments?post=942"}],"version-history":[{"count":1,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts\/942\/revisions"}],"predecessor-version":[{"id":1621,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts\/942\/revisions\/1621"}],"wp:attachment":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/media?parent=942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/categories?post=942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/tags?post=942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}